Key facts
- This page summarizes Hafrun Fridriksdottir's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 19 May 2022, 07:31.
Hafrun Fridriksdottir - 17 May 2022 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
- Reporting relationship
- Executive VP, Global R&D
- Issuer ticker
- TEVA
- Reported as of
- 17 May 2022
- Net transaction value
- -$1,068,067
- SEC form
- 4
- Accepted by SEC
- 19 May 2022, 07:31:18 UTC
- Prior SEC filing
- 08 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dov Bergwerk as attorney-in-fact for Hafrun Fridriksdottir
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Hafrun Fridriksdottir filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 19 May 2022.
Change
- Previous filing in this sequence was filed on 08 Mar 2022.
- Current net transaction value: -$1,068,067.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TEVA
transaction
Ordinary Shares
Sale
- Transaction value
- $1,068,067
- Shares
- -130,000
- Change %
- -99%
- Price
- $8.22
- Shares after
- 1,387
- Date
- 17 May 2022
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.185 to $8.240, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
Footnote F3
The shares held by the reporting person prior to the sale reported in this Form 4 included 5,300 Ordinary Shares previously issued to the reporting person in exempt transactions in connection with the settlement of certain equity-based awards granted to the reporting person, which were inadvertently omitted from the reporting person's previously reported amount of securities beneficially owned.